Glenmark Specialty Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLENMARK SPECIALTY, and when can generic versions of GLENMARK SPECIALTY drugs launch?
GLENMARK SPECIALTY has one approved drug.
There are fourteen US patents protecting GLENMARK SPECIALTY drugs.
There are eighty patent family members on GLENMARK SPECIALTY drugs in thirty-two countries and twelve supplementary protection certificates in eleven countries.
Summary for Glenmark Specialty
International Patents: | 80 |
US Patents: | 14 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Glenmark Specialty
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 10,561,672 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 9,370,483 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 10,548,907 | ⤷ Sign Up | ⤷ Sign Up | ||||
Glenmark Specialty | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | 10,376,526 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Glenmark Specialty Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Croatia | P20211515 | ⤷ Sign Up |
Russian Federation | 2020126691 | ⤷ Sign Up |
Japan | 2018123157 | ⤷ Sign Up |
Japan | 6664358 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glenmark Specialty Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3043773 | 2190041-0 | Sweden | ⤷ Sign Up | PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; NAT. REG. NO/DATE: MT NR 60226 20210519; FIRST REG.: AT APPROVAL NR 140638 20210426 |
3043773 | 2021045 | Norway | ⤷ Sign Up | PRODUCT NAME: MOMETASON ELLER ET SALT DERAV OG OLOPATADIN ELLER ET SALT DERAV; NAT. REG. NO/DATE: 20-13278 20210709; FIRST REG. NO/DATE: 140638 20210426 |
3043773 | 301154 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MOMETASON OF EEN ZOUT DAARVAN EN OLOPATADINE OF EEN ZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 126186 20211014; FIRST REGISTRATION: AT 140638 20210426 |
3043773 | 2022C/520 | Belgium | ⤷ Sign Up | PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.